Andrew G. Robinson
Kingston General Hospital
CancerInternal medicineSurgeryOncologyRandomized controlled trialIntensive care medicineStage (cooking)Adverse effectHazard ratioTesticular cancerLung cancerChemotherapyCancer registryMEDLINEPembrolizumabProgression-free survivalPD-L1PopulationIn patientBreast cancerClinical trialMedicine
Publications 68
#1Andrew G. Robinson (Queen's University)H-Index: 17
#2Jennifer O’Donnell (Queen's University)H-Index: 3
Last. Michael Brundage (Queen's University)H-Index: 62
view all 6 authors...
Abstract null null Background null Progression-free survival (PFS) is often used as a clinical trials outcome for evaluating new therapies for solid tumors. While PFS is a validated surrogate for overall survival (OS) or quality of life (QOL) in some settings, it is increasingly used in contexts where surrogacy is not established. PFS is a composite endpoint of survival, symptomatic progression, and imaging-only progression. The intrinsic value of asymptomatic (imaging-only) progression from the...
#1Jaclyn Beca (Cancer Care Ontario)H-Index: 10
#2Shaun Walsh (Cancer Care Ontario)
Last. Kelvin K. W. Chan (Sunnybrook Health Sciences Centre)H-Index: 35
view all 8 authors...
Introduction null While no direct comparative data exist for crizotinib in ROS1+ non-small cell lung cancer (NSCLC), studies have suggested clinical benefit with this targeted agent. The objective of this study was to assess the cost-effectiveness of crizotinib compared to standard platinum-doublet chemotherapy for first-line treatment of ROS1+ advanced NSCLC. null Methods null A Markov model was developed with a 10-year time horizon from the perspective of the Canadian publicly-funded health ca...
#1Adi Kartolo (Queen's University)H-Index: 4
#2Ryan Holstead (Queen's University)H-Index: 2
Last. Francisco E. Vera-Badillo (Queen's University)H-Index: 24
view all 5 authors...
Abstract null null Objective null To define the impact of first-line dual therapy involving immune checkpoint inhibitors (ICI) on survival outcomes in patients with advanced renal cell carcinoma (aRCC) of International Metastatic RCC Database Consortium favourable-risk. null null null Materials and Methods null Systematic review of Medline, EMBASE, and Cochrane Central Register of Controlled trials were conducted to select all phase II/III randomized clinical trials involving first-line, palliat...
#2Paul Nguyen (Queen's University)H-Index: 4
Last. Timothy P. HannaH-Index: 16
view all 0 authors...
Ensuring high quality end of life (EOL) care is necessary for people with advanced non-small-cell lung cancer (NSCLC), given its high incidence, mortality and symptom burden. Aggressive EOL care can adversely affect the quality of life of NSCLC patients without providing meaningful oncologic benefit. Objectives: (1) To describe EOL health services quality indicators and timing of palliative care consultation provided to patients dying of NSCLC. (2) To examine associations between aggressive and ...
ABSTRACT null INTRODUCTION null We retrospectively evaluated outcomes in patients with PD-L1–positive non‒small-cell lung cancer (NSCLC) to determine whether baseline (ie, at study enrollment) brain metastases were associated with efficacy of pembrolizumab versus chemotherapy. null METHODS null We pooled data for patients with previously treated or untreated PD-L1‒positive (tumor proportion score [TPS], ≥1%) advanced/metastatic NSCLC in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNO...
#1Bishal Gyawali (Queen's University)H-Index: 25
#2Rebecca Griffiths (Queen's University)H-Index: 5
Last. Christopher M. Booth (Queen's University)H-Index: 36
view all 6 authors...
INTRODUCTION Imaging is an integral component of active surveillance following orchiectomy for stage 1 non-seminoma (NSGCT) and seminoma germ cell tumors. In this population-based study, we describe use of imaging among patients with early-stage testicular cancer and evaluate whether they are concordant with guideline recommendations. METHODS This is a population-based, retrospective cohort study to describe utilization of imaging among all patients with early-stage testicular cancer treated wit...
#1Martin ReckH-Index: 86
#2Delvys Rodriguez-Abreu (ULPGC: University of Las Palmas de Gran Canaria)H-Index: 33
Last. Julie R. Brahmer (Johns Hopkins University)H-Index: 92
view all 19 authors...
PURPOSEWe report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 ( identifier: NCT02142738) is an op...
#1Andrew G. RobinsonH-Index: 17
#2David VicenteH-Index: 19
Last. Luis Paz-AresH-Index: 84
view all 18 authors...
#1Andrew G. Robinson (Queen's University)H-Index: 17
#2Jason P. Izard (Queen's University)H-Index: 15
Last. Francisco E. Vera-Badillo (Queen's University)H-Index: 24
view all 3 authors...
For patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after an androgen receptor axis-targeted therapy and docetaxel, poly (ADP-ribose) polymerase (PARP) inhibitors and chemotherapy with cabazitaxel have shown promise. We address the trials for the two approaches and consider possible sequencing of these drugs. We suggest that only patients with a BRCA2 mutation should receive a PARP inhibitor, and docetaxel or cabazitaxel should be favored in the absence of BRCA2...
#1Michael J. Raphael (U of T: University of Toronto)H-Index: 10
#2Sumit Gupta (International Council for the Exploration of the Sea)H-Index: 28
Last. Christopher M. Booth (Queen's University)H-Index: 36
view all 9 authors...
PURPOSE Testicular cancer survivors may experience mental illness as a consequence of their cancer diagnosis and treatment. METHODS All incident cases of testicular cancer treated with orchiectomy in Ontario, Canada (2000-2010), were identified using the Ontario Cancer Registry. Cases were matched to controls in a 1:5 ratio on age and geography. Population-level databases were used to identify mental health service use episodes; outpatient use included visits to a general practitioner for a ment...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.